Advancing cardiovascular medicine through a first-in-class pipeline of synthetic omega-3 metabolites.

OMEICOS Therapeutics is developing oral, first-in-class, small molecules for the prevention and treatment of cardiovascular diseases, initially focusing on aterial fibrillation (AF). The company's novel, small molecule AF therapy is based on proprietary synthetic analogues of omega-3 fatty acid metabolites.